Market capitalization | €3.77b |
Enterprise Value | €3.75b |
P/E (TTM) P/E ratio | 28.06 |
EV/FCF (TTM) EV/FCF | 81.55 |
EV/Sales (TTM) EV/Sales | 3.93 |
P/S ratio (TTM) P/S ratio | 3.94 |
P/B ratio (TTM) P/B ratio | 4.54 |
Dividend yield | 0.64% |
Last dividend (FY25) | €0.16 |
As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.
11 Analysts have issued a SCHOTT Pharma forecast:
11 Analysts have issued a SCHOTT Pharma forecast:
Dec '24 |
+/-
%
|
||
Revenue | 955 955 |
-
|
|
Gross Profit | 315 315 |
-
|
|
EBITDA | 233 233 |
-
|
EBIT (Operating Income) EBIT | 164 164 |
-
|
Net Profit | 134 134 |
-
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Head office | Germany |
CEO | Andreas Reisse |
Employees | 4,689 |
Founded | 2022 |
Website | www.schott.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.